Search

Search Constraints

You searched for: Author/Creator Breccia, M.

Search Results

1. 198 OUTCOME OF AZACITIDINE TREATMENT AND INCIDENCE OF FEBRILE EVENTS IN "REAL WORLD" PATIENTS WITH MDS OR LOW-BLAST COUNT AML. Issue 1 (April 2015)

2. A Real-Life Study of Deferasirox in Patients with Higher Risk Myelodysplastic Syndromes. (April 2017)

3. Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. Issue 8 (August 2015)

4. Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. Issue 8 (August 2015)

5. Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy. (April 2023)

6. Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes. (August 2018)

8. P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME. (23rd June 2022)

9. P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB. (23rd June 2022)

10. P1706: CLINICAL UTILITY OF ONLINE MONITORING OF PATIENT-REPORTED SYMPTOMS IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN REAL-LIFE PRACTICE. (23rd June 2022)